PHARMACOLOGICAL RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2251955, encodeId=5793225195523, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗;肿瘤代谢 经验分享：一个字，快，前后不到50天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=57qU1AHBWEoibpHCiaMRR2PA&s=100, createdBy=cf4e2562414, createdName=生而为医, createdTime=Fri Feb 14 18:29:31 CST 2025, time=2025-02-14, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2252248, encodeId=d089225224821, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：该期刊优先收录基于大型数据集/长期追踪的队列研究，理论推演类论文接受率低于15% 我是植物提取小分子的文章，没过，建议我改投😂 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 22:08:05 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248088, encodeId=e6d42248088a6, content=效率真高，投稿第二天with editor然后reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64406517662, createdName=ms6000000673439938, createdTime=Tue Jan 14 22:52:45 CST 2025, time=2025-01-14, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2241951, encodeId=3c3b2241951f1, content=求问研究性论文的checklist应该怎么填啊？For studies with bioactive molecules derived from medicinal plants, natural products and TCM preparations The submission will automatically be rejected if questions 39-43 are not marked “yes”如果不选yes，会有什么影响吗，会直接拒稿吗？主要我的文章里确实没有呀！这怎么搞？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Thu Dec 12 04:11:56 CST 2024, time=2024-12-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=416, replyNumber=36, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules，若我文章不属于这两项内容，这两个框框还需要进行勾选吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津)]

2025-02-14 生而为医来自台湾省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：免疫治疗;肿瘤代谢
经验分享：一个字，快，前后不到50天。

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2251955, encodeId=5793225195523, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗;肿瘤代谢 经验分享：一个字，快，前后不到50天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=57qU1AHBWEoibpHCiaMRR2PA&s=100, createdBy=cf4e2562414, createdName=生而为医, createdTime=Fri Feb 14 18:29:31 CST 2025, time=2025-02-14, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2252248, encodeId=d089225224821, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：该期刊优先收录基于大型数据集/长期追踪的队列研究，理论推演类论文接受率低于15% 我是植物提取小分子的文章，没过，建议我改投😂 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 22:08:05 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248088, encodeId=e6d42248088a6, content=效率真高，投稿第二天with editor然后reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64406517662, createdName=ms6000000673439938, createdTime=Tue Jan 14 22:52:45 CST 2025, time=2025-01-14, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2241951, encodeId=3c3b2241951f1, content=求问研究性论文的checklist应该怎么填啊？For studies with bioactive molecules derived from medicinal plants, natural products and TCM preparations The submission will automatically be rejected if questions 39-43 are not marked “yes”如果不选yes，会有什么影响吗，会直接拒稿吗？主要我的文章里确实没有呀！这怎么搞？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Thu Dec 12 04:11:56 CST 2024, time=2024-12-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=416, replyNumber=36, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules，若我文章不属于这两项内容，这两个框框还需要进行勾选吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津)]

2025-02-16 ms5000002977722150 来自上海

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：中药
经验分享：该期刊优先收录基于大型数据集/长期追踪的队列研究，理论推演类论文接受率低于15%
我是植物提取小分子的文章，没过，建议我改投😂

17 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2251955, encodeId=5793225195523, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗;肿瘤代谢 经验分享：一个字，快，前后不到50天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=57qU1AHBWEoibpHCiaMRR2PA&s=100, createdBy=cf4e2562414, createdName=生而为医, createdTime=Fri Feb 14 18:29:31 CST 2025, time=2025-02-14, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2252248, encodeId=d089225224821, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：该期刊优先收录基于大型数据集/长期追踪的队列研究，理论推演类论文接受率低于15% 我是植物提取小分子的文章，没过，建议我改投😂 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 22:08:05 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248088, encodeId=e6d42248088a6, content=效率真高，投稿第二天with editor然后reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64406517662, createdName=ms6000000673439938, createdTime=Tue Jan 14 22:52:45 CST 2025, time=2025-01-14, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2241951, encodeId=3c3b2241951f1, content=求问研究性论文的checklist应该怎么填啊？For studies with bioactive molecules derived from medicinal plants, natural products and TCM preparations The submission will automatically be rejected if questions 39-43 are not marked “yes”如果不选yes，会有什么影响吗，会直接拒稿吗？主要我的文章里确实没有呀！这怎么搞？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Thu Dec 12 04:11:56 CST 2024, time=2024-12-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=416, replyNumber=36, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules，若我文章不属于这两项内容，这两个框框还需要进行勾选吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津)]

2025-01-14 ms6000000673439938 来自甘肃省

效率真高，投稿第二天with editor然后reject

17 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2251955, encodeId=5793225195523, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗;肿瘤代谢 经验分享：一个字，快，前后不到50天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=57qU1AHBWEoibpHCiaMRR2PA&s=100, createdBy=cf4e2562414, createdName=生而为医, createdTime=Fri Feb 14 18:29:31 CST 2025, time=2025-02-14, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2252248, encodeId=d089225224821, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：该期刊优先收录基于大型数据集/长期追踪的队列研究，理论推演类论文接受率低于15% 我是植物提取小分子的文章，没过，建议我改投😂 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 22:08:05 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248088, encodeId=e6d42248088a6, content=效率真高，投稿第二天with editor然后reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64406517662, createdName=ms6000000673439938, createdTime=Tue Jan 14 22:52:45 CST 2025, time=2025-01-14, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2241951, encodeId=3c3b2241951f1, content=求问研究性论文的checklist应该怎么填啊？For studies with bioactive molecules derived from medicinal plants, natural products and TCM preparations The submission will automatically be rejected if questions 39-43 are not marked “yes”如果不选yes，会有什么影响吗，会直接拒稿吗？主要我的文章里确实没有呀！这怎么搞？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Thu Dec 12 04:11:56 CST 2024, time=2024-12-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=416, replyNumber=36, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules，若我文章不属于这两项内容，这两个框框还需要进行勾选吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津)]

2024-12-12 ms4000000265024223 来自山东省

求问研究性论文的checklist应该怎么填啊？For studies with bioactive molecules derived from medicinal plants, natural products and TCM preparations The submission will automatically be rejected if questions 39-43 are not marked “yes”如果不选yes，会有什么影响吗，会直接拒稿吗？主要我的文章里确实没有呀！这怎么搞？

25 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2251955, encodeId=5793225195523, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗;肿瘤代谢 经验分享：一个字，快，前后不到50天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=57qU1AHBWEoibpHCiaMRR2PA&s=100, createdBy=cf4e2562414, createdName=生而为医, createdTime=Fri Feb 14 18:29:31 CST 2025, time=2025-02-14, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2252248, encodeId=d089225224821, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：该期刊优先收录基于大型数据集/长期追踪的队列研究，理论推演类论文接受率低于15% 我是植物提取小分子的文章，没过，建议我改投😂 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 22:08:05 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248088, encodeId=e6d42248088a6, content=效率真高，投稿第二天with editor然后reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64406517662, createdName=ms6000000673439938, createdTime=Tue Jan 14 22:52:45 CST 2025, time=2025-01-14, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2241951, encodeId=3c3b2241951f1, content=求问研究性论文的checklist应该怎么填啊？For studies with bioactive molecules derived from medicinal plants, natural products and TCM preparations The submission will automatically be rejected if questions 39-43 are not marked “yes”如果不选yes，会有什么影响吗，会直接拒稿吗？主要我的文章里确实没有呀！这怎么搞？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Thu Dec 12 04:11:56 CST 2024, time=2024-12-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=416, replyNumber=36, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules，若我文章不属于这两项内容，这两个框框还需要进行勾选吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津)]

2024-04-16 小胖子罗军来自上海

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：中药单体
经验分享：不收植物提取小分子的文章了，让改投到子刊

120 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2251955, encodeId=5793225195523, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗;肿瘤代谢 经验分享：一个字，快，前后不到50天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=57qU1AHBWEoibpHCiaMRR2PA&s=100, createdBy=cf4e2562414, createdName=生而为医, createdTime=Fri Feb 14 18:29:31 CST 2025, time=2025-02-14, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2252248, encodeId=d089225224821, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：该期刊优先收录基于大型数据集/长期追踪的队列研究，理论推演类论文接受率低于15% 我是植物提取小分子的文章，没过，建议我改投😂 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 22:08:05 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248088, encodeId=e6d42248088a6, content=效率真高，投稿第二天with editor然后reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64406517662, createdName=ms6000000673439938, createdTime=Tue Jan 14 22:52:45 CST 2025, time=2025-01-14, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2241951, encodeId=3c3b2241951f1, content=求问研究性论文的checklist应该怎么填啊？For studies with bioactive molecules derived from medicinal plants, natural products and TCM preparations The submission will automatically be rejected if questions 39-43 are not marked “yes”如果不选yes，会有什么影响吗，会直接拒稿吗？主要我的文章里确实没有呀！这怎么搞？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Thu Dec 12 04:11:56 CST 2024, time=2024-12-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=416, replyNumber=36, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules，若我文章不属于这两项内容，这两个框框还需要进行勾选吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津)]

2020-12-02 泪湿青衣

审稿速度:1.0 | 投稿命中率:75.0
经验分享：一审20天，给了一个月修回，修回后第二天立马接收了

416 36

展开36条回复

[GetPortalCommentsPageByObjectIdResponse(id=2251955, encodeId=5793225195523, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗;肿瘤代谢 经验分享：一个字，快，前后不到50天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=57qU1AHBWEoibpHCiaMRR2PA&s=100, createdBy=cf4e2562414, createdName=生而为医, createdTime=Fri Feb 14 18:29:31 CST 2025, time=2025-02-14, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2252248, encodeId=d089225224821, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：该期刊优先收录基于大型数据集/长期追踪的队列研究，理论推演类论文接受率低于15% 我是植物提取小分子的文章，没过，建议我改投😂 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 22:08:05 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248088, encodeId=e6d42248088a6, content=效率真高，投稿第二天with editor然后reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64406517662, createdName=ms6000000673439938, createdTime=Tue Jan 14 22:52:45 CST 2025, time=2025-01-14, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2241951, encodeId=3c3b2241951f1, content=求问研究性论文的checklist应该怎么填啊？For studies with bioactive molecules derived from medicinal plants, natural products and TCM preparations The submission will automatically be rejected if questions 39-43 are not marked “yes”如果不选yes，会有什么影响吗，会直接拒稿吗？主要我的文章里确实没有呀！这怎么搞？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Thu Dec 12 04:11:56 CST 2024, time=2024-12-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=416, replyNumber=36, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules，若我文章不属于这两项内容，这两个框框还需要进行勾选吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津)]

2023-11-07 ms7000001072468055 来自北京

请问综述的checklist有模板吗？

114 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2251955, encodeId=5793225195523, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗;肿瘤代谢 经验分享：一个字，快，前后不到50天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=57qU1AHBWEoibpHCiaMRR2PA&s=100, createdBy=cf4e2562414, createdName=生而为医, createdTime=Fri Feb 14 18:29:31 CST 2025, time=2025-02-14, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2252248, encodeId=d089225224821, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：该期刊优先收录基于大型数据集/长期追踪的队列研究，理论推演类论文接受率低于15% 我是植物提取小分子的文章，没过，建议我改投😂 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 22:08:05 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248088, encodeId=e6d42248088a6, content=效率真高，投稿第二天with editor然后reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64406517662, createdName=ms6000000673439938, createdTime=Tue Jan 14 22:52:45 CST 2025, time=2025-01-14, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2241951, encodeId=3c3b2241951f1, content=求问研究性论文的checklist应该怎么填啊？For studies with bioactive molecules derived from medicinal plants, natural products and TCM preparations The submission will automatically be rejected if questions 39-43 are not marked “yes”如果不选yes，会有什么影响吗，会直接拒稿吗？主要我的文章里确实没有呀！这怎么搞？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Thu Dec 12 04:11:56 CST 2024, time=2024-12-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=416, replyNumber=36, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules，若我文章不属于这两项内容，这两个框框还需要进行勾选吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津)]

2022-07-24 石烽

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：主动脉夹层
经验分享：5.3 Submitted to Journal
5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段)
5.10 Under Review
6.10 Required Reviews Completed
6.12 Decision in Process
6.14 Major Revise (20天期限)
7.2 Resubmitted to Journal
7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段)
7.11 Under Review
7.20 Required Reviews Completed
7.20 Decision in Process
7.23 Accept
7.23 Pre-proof online (DOI )
要点：
1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。
2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。
3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核
祝各位的Paper早日Accept !!!

230 45

展开45条回复

[GetPortalCommentsPageByObjectIdResponse(id=2251955, encodeId=5793225195523, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗;肿瘤代谢 经验分享：一个字，快，前后不到50天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=57qU1AHBWEoibpHCiaMRR2PA&s=100, createdBy=cf4e2562414, createdName=生而为医, createdTime=Fri Feb 14 18:29:31 CST 2025, time=2025-02-14, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2252248, encodeId=d089225224821, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：该期刊优先收录基于大型数据集/长期追踪的队列研究，理论推演类论文接受率低于15% 我是植物提取小分子的文章，没过，建议我改投😂 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 22:08:05 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248088, encodeId=e6d42248088a6, content=效率真高，投稿第二天with editor然后reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64406517662, createdName=ms6000000673439938, createdTime=Tue Jan 14 22:52:45 CST 2025, time=2025-01-14, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2241951, encodeId=3c3b2241951f1, content=求问研究性论文的checklist应该怎么填啊？For studies with bioactive molecules derived from medicinal plants, natural products and TCM preparations The submission will automatically be rejected if questions 39-43 are not marked “yes”如果不选yes，会有什么影响吗，会直接拒稿吗？主要我的文章里确实没有呀！这怎么搞？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Thu Dec 12 04:11:56 CST 2024, time=2024-12-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=416, replyNumber=36, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules，若我文章不属于这两项内容，这两个框框还需要进行勾选吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津)]

2024-01-03 1225de92m39暂无昵称来自广东省

请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules，若我文章不属于这两项内容，这两个框框还需要进行勾选吗？

71 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2251955, encodeId=5793225195523, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗;肿瘤代谢 经验分享：一个字，快，前后不到50天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=57qU1AHBWEoibpHCiaMRR2PA&s=100, createdBy=cf4e2562414, createdName=生而为医, createdTime=Fri Feb 14 18:29:31 CST 2025, time=2025-02-14, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2252248, encodeId=d089225224821, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：该期刊优先收录基于大型数据集/长期追踪的队列研究，理论推演类论文接受率低于15% 我是植物提取小分子的文章，没过，建议我改投😂 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 22:08:05 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248088, encodeId=e6d42248088a6, content=效率真高，投稿第二天with editor然后reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64406517662, createdName=ms6000000673439938, createdTime=Tue Jan 14 22:52:45 CST 2025, time=2025-01-14, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2241951, encodeId=3c3b2241951f1, content=求问研究性论文的checklist应该怎么填啊？For studies with bioactive molecules derived from medicinal plants, natural products and TCM preparations The submission will automatically be rejected if questions 39-43 are not marked “yes”如果不选yes，会有什么影响吗，会直接拒稿吗？主要我的文章里确实没有呀！这怎么搞？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d5e8174870, createdName=ms4000000265024223, createdTime=Thu Dec 12 04:11:56 CST 2024, time=2024-12-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=416, replyNumber=36, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=230, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178950, encodeId=e31a21e895082, content=请问这个杂志里的author checklist中的两个勾选框分别是for Meta-analyses only和for studies with bioactive molecules，若我文章不属于这两项内容，这两个框框还需要进行勾选吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04202326131, createdName=1225de92m39暂无昵称, createdTime=Wed Jan 03 09:18:31 CST 2024, time=2024-01-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津)]

2023-11-30 周大-Jagger 来自天津

请问这个投稿后，必须要每个作者邮件确认么？

91 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务